左氧氟沙星口服与序贯治疗轻症社区获得性肺炎的临床效果及成本效益分析  

Clinical effects and cost effectiveness analysis of oral and sequential therapy of levofloxacin for mild community acquired pneumonia

作　　者：张学平[1] 翟云青[1] 赵娜[1] 何旦旦[1] 刘双双 马小芬 ZHANG Xue-ping;ZHAI Yun-qing;ZHAO Na;HE Dan-dan;LIU Shuang-shuang;MA Xiao-fen(Respiratory Medicine Department,Binzhou Center Hospital,Binzhou 251700,China)

机构地区：[1]滨州市中心医院呼吸内科

出　　处：《临床医学研究与实践》2019年第20期29-30,共2页Clinical Research and Practice

摘　　要：目的探讨左氧氟沙星口服与序贯治疗轻症社区获得性肺炎(CAP)的临床效果,并评价其成本效益。方法选取于我院门诊就诊的228例轻症CAP患者为研究对象,将其按随机数字表法分成观察组和对照组,各114例。观察组给予口服左氧氟沙星,对照组给予左氧氟沙星序贯治疗。观察比较两组临床效果和成本效益。结果两组治疗总有效率无显著差异(P>0.05);两组退热时间、呼吸困难消失时间及治疗时间无显著差异(P>0.05);观察组药物费用明显低于对照组(P<0.05)。结论口服左氧氟沙星在轻症CAP患者治疗中具有良好的临床疗效及更低的医疗成本,值得临床应用。Objective To investigate the clinical effects of oral and sequential therapy of levofloxacin for mild community acquired pneumonia(CAP),and to evaluate the cost effectiveness.Methods A total of 228 patients with mild CAP admitted in the outpatient department of our hospital were selected as research objects and divided into observation group and control group according to random number table method,with 114 cases in each group.The observation group received levofloxacin orally,and the control group received sequential therapy of levofloxacin.The clinical effects and cost effectiveness of the two groups were observed and compared.Results There was no significant difference in total effective rate of treatment between the two groups(P>0.05).There were no significant differences in antipyretic time,disappearance time of dyspnea and treatment time between the two groups(P>0.05).The drug cost in the observation group was significantly lower than that in the control group(P<0.05).Conclusion Oral levofloxacin has good clinical efficacy and lower medical cost in the treatment of mild CAP patients,which is worthy of clinical application.

关 键 词：左氧氟沙星 社区获得性肺炎 成本效益 

分 类 号：R563.1[医药卫生—呼吸系统]